Loading...
XHKG9996
Market cap335mUSD
Jan 07, Last price  
3.99HKD
1D
1.27%
1Q
4.18%
IPO
-85.52%
Name

Peijia Medical Ltd

Chart & Performance

D1W1MN
XHKG:9996 chart
P/E
P/S
5.57
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
2.17%
Rev. gr., 5y
%
Revenues
441m
+75.86%
018,699,00038,655,000136,534,000250,833,000441,126,000
Net income
-393m
L-3.75%
-82,625,000-841,264,000-2,068,656,000-574,216,000-407,809,000-392,525,000
CFO
-583m
L+55.10%
-38,728,000-102,590,000-181,100,000-436,368,000-376,196,000-583,485,000

Profile

Peijia Medical Limited engages in the research and development of transcatheter valve therapeutic and neuro interventional procedural medical devices. Its transcatheter valve therapeutic products include TaurusOne, a transcatheter aortic valve replacement (TAVR) system; TaurusElite, a retrievable TAVR system; TaurusNXT, a non-glutaraldehyde crosslinking dry-tissue TAVR system; TaurusWave, a lithotripsy valvuloplasty system; TaurusApex, a polymer leaflets TAVR system; Trilogy, a TAVR System; HighLife, a transseptal mitral value replacement system; SpyderOne, a transapical transcatheter mitral valve replacement (TMVR) system; Sutra, a TMV coaptation augmentation system; GeminiOne, a transcatheter edge-to-edge repair system; MonarQ and Peijia, which are transcatheter tricuspid valve replacement systems; TaurusAtlas, a transfemoral ballon catheter; TaurusExplora, a pre-shaped guidewire; and introducer sheath. The company also offers Jasper and Presgo, that are detachable coils; Jasper SS detachable coil; intracranial adjunctive stents; SacSpeed, a balloon dilatation catheter; Tethys AS, an aspiration catheter; Syphonet, a stent retriever; Neway, a balloon microcatheter; Fluxcap, a balloon guiding catheter; NeuroStellar, an intracranial stent; Presgo microcatheter and micro guidewire; Heralder guiding catheter and distal access catheter; Tethys, an intermediate catheter; and Jasper power supply. In addition, it engages in the trading business. Peijia Medical Limited was incorporated in 2012 and is headquartered in Suzhou, the People's Republic of China.
IPO date
May 15, 2020
Employees
1,006
Domiciled in
CN
Incorporated in
KY

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑12
Income
Revenues
441,126
75.86%
250,833
83.71%
Cost of revenue
875,794
823,345
Unusual Expense (Income)
NOPBT
(434,668)
(572,512)
NOPBT Margin
Operating Taxes
1,052
9,574
Tax Rate
NOPAT
(435,720)
(582,086)
Net income
(392,525)
-3.75%
(407,809)
-28.98%
Dividends
Dividend yield
Proceeds from repurchase of equity
4,055
(8,258)
BB yield
Debt
Debt current
16,414
58,953
Long-term debt
208,434
75,814
Deferred revenue
1,720
Other long-term liabilities
38,914
(22,040)
Net debt
(1,111,190)
(2,023,816)
Cash flow
Cash from operating activities
(583,485)
(376,196)
CAPEX
(175,624)
(130,412)
Cash from investing activities
(386,291)
(463,277)
Cash from financing activities
85,108
117,438
FCF
(723,042)
(720,145)
Balance
Cash
942,925
1,743,097
Long term investments
393,113
415,486
Excess cash
1,313,982
2,146,041
Stockholders' equity
(4,104,885)
(3,648,716)
Invested Capital
6,639,014
6,410,535
ROIC
ROCE
EV
Common stock shares outstanding
679,275
673,160
Price
Market cap
EV
EBITDA
(391,866)
(538,529)
EV/EBITDA
Interest
178
2,316
Interest/NOPBT